Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019
- PMID: 32162523
- DOI: 10.1021/acs.jnatprod.9b01285
Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019
Abstract
This review is an updated and expanded version of the five prior reviews that were published in this journal in 1997, 2003, 2007, 2012, and 2016. For all approved therapeutic agents, the time frame has been extended to cover the almost 39 years from the first of January 1981 to the 30th of September 2019 for all diseases worldwide and from ∼1946 (earliest so far identified) to the 30th of September 2019 for all approved antitumor drugs worldwide. As in earlier reviews, only the first approval of any drug is counted, irrespective of how many "biosimilars" or added approvals were subsequently identified. As in the 2012 and 2016 reviews, we have continued to utilize our secondary subdivision of a "natural product mimic", or "NM", to join the original primary divisions, and the designation "natural product botanical", or "NB", to cover those botanical "defined mixtures" now recognized as drug entities by the FDA (and similar organizations). From the data presented in this review, the utilization of natural products and/or synthetic variations using their novel structures, in order to discover and develop the final drug entity, is still alive and well. For example, in the area of cancer, over the time frame from 1946 to 1980, of the 75 small molecules, 40, or 53.3%, are N or ND. In the 1981 to date time frame the equivalent figures for the N* compounds of the 185 small molecules are 62, or 33.5%, though to these can be added the 58 S* and S*/NMs, bringing the figure to 64.9%. In other areas, the influence of natural product structures is quite marked with, as expected from prior information, the anti-infective area being dependent on natural products and their structures, though as can be seen in the review there are still disease areas (shown in Table 2) for which there are no drugs derived from natural products. Although combinatorial chemistry techniques have succeeded as methods of optimizing structures and have been used very successfully in the optimization of many recently approved agents, we are still able to identify only two de novo combinatorial compounds (one of which is a little speculative) approved as drugs in this 39-year time frame, though there is also one drug that was developed using the "fragment-binding methodology" and approved in 2012. We have also added a discussion of candidate drug entities currently in clinical trials as "warheads" and some very interesting preliminary reports on sources of novel antibiotics from Nature due to the absolute requirement for new agents to combat plasmid-borne resistance genes now in the general populace. We continue to draw the attention of readers to the recognition that a significant number of natural product drugs/leads are actually produced by microbes and/or microbial interactions with the "host from whence it was isolated"; thus we consider that this area of natural product research should be expanded significantly.
Similar articles
-
Natural Products as Sources of New Drugs from 1981 to 2014.J Nat Prod. 2016 Mar 25;79(3):629-61. doi: 10.1021/acs.jnatprod.5b01055. Epub 2016 Feb 7. J Nat Prod. 2016. PMID: 26852623 Review.
-
Natural product discovery: past, present, and future.J Ind Microbiol Biotechnol. 2016 Mar;43(2-3):155-76. doi: 10.1007/s10295-015-1723-5. Epub 2016 Jan 6. J Ind Microbiol Biotechnol. 2016. PMID: 26739136 Review.
-
Natural products as sources of new drugs over the 30 years from 1981 to 2010.J Nat Prod. 2012 Mar 23;75(3):311-35. doi: 10.1021/np200906s. Epub 2012 Feb 8. J Nat Prod. 2012. PMID: 22316239 Free PMC article. Review.
-
Natural products as sources of new drugs over the last 25 years.J Nat Prod. 2007 Mar;70(3):461-77. doi: 10.1021/np068054v. Epub 2007 Feb 20. J Nat Prod. 2007. PMID: 17309302 Review.
-
Natural products as sources of new drugs over the period 1981-2002.J Nat Prod. 2003 Jul;66(7):1022-37. doi: 10.1021/np030096l. J Nat Prod. 2003. PMID: 12880330 Review.
Cited by
-
Medical ethnobotany.BMC Complement Med Ther. 2024 Jun 5;24(1):216. doi: 10.1186/s12906-024-04515-0. BMC Complement Med Ther. 2024. PMID: 38840100 Free PMC article.
-
(+)/(-)-Gerbeloid A, a pair of unprecedented coumarin-based polycyclic meroterpenoid enantiomers from Gerbera piloselloides: Structural elucidation, semi-synthesis, and lipid-lowering activity.Acta Pharm Sin B. 2024 Jun;14(6):2657-2668. doi: 10.1016/j.apsb.2024.03.035. Epub 2024 Mar 30. Acta Pharm Sin B. 2024. PMID: 38828137 Free PMC article.
-
Neocarzilin Inhibits Cancer Cell Proliferation via BST-2 Degradation, Resulting in Lipid Raft-Trapped EGFR.JACS Au. 2024 May 8;4(5):1833-1840. doi: 10.1021/jacsau.4c00039. eCollection 2024 May 27. JACS Au. 2024. PMID: 38818080 Free PMC article.
-
Synthetic biology to revive microbial natural product discovery.mLife. 2023 Jun 22;2(2):123-125. doi: 10.1002/mlf2.12071. eCollection 2023 Jun. mLife. 2023. PMID: 38817621 Free PMC article. No abstract available.
-
Bacillamide D produced by Bacillus cereus from the mouse intestinal bacterial collection (miBC) is a potent cytotoxin in vitro.Commun Biol. 2024 May 28;7(1):655. doi: 10.1038/s42003-024-06208-3. Commun Biol. 2024. PMID: 38806706 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials